 Connection
Shmuel Yaccoby to Transplantation, Heterologous
This is a "connection" page, showing publications Shmuel Yaccoby has written about Transplantation, Heterologous.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.260 |
|
|
|
-
Qiang YW, Shaughnessy JD, Yaccoby S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood. 2008 Jul 15; 112(2):374-82.
Score: 0.076
-
Epstein J, Yaccoby S. The SCID-hu myeloma model. Methods Mol Med. 2005; 113:183-90.
Score: 0.061
-
Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, Epstein J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood. 2002 Dec 01; 100(12):4162-8.
Score: 0.052
-
Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol. 2002 Feb; 116(2):278-90.
Score: 0.050
-
van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD, Barlogie B, Yaccoby S, Afar DE. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009 Sep; 8(9):2616-24.
Score: 0.021
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|